Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma

Nature Communications

Volumn 6, Issue , 2015, Pages

  Shao, Huilin ^a,e   Chung, Jaehoon ^a,f   Lee, Kyungheon ^a   Balaj, Leonora ^a,b   Min, Changwook ^a   Carter, Bob S ^c   Hochberg, Fred H ^c,d   Breakefield, Xandra O ^a,b   Lee, Hakho ^a   Weissleder, Ralph ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f INSTITUTE OF MICROELECTRONICS   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; DACARBAZINE; TEMOZOLOMIDE; TUMOR MARKER;

DISEASE TREATMENT; DRUG RESISTANCE; ENZYME ACTIVITY; GENE EXPRESSION; METHYLATION; RNA; TUMOR;

ARTICLE; BLOOD BRAIN BARRIER; CANCER RESISTANCE; CELL CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; EXOSOME; GENE PRODUCT; GLIOBLASTOMA; HUMAN; HUMAN CELL; METHYLATION; MICROFLUIDICS; PROMOTER REGION; RADIOTHERAPY; REVERSE TRANSCRIPTION; RNA ANALYSIS; RNA EXTRACTION; THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOMAGNETIC SEPARATION; METABOLISM; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; EXOSOMES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOMAGNETIC SEPARATION; MICE, NUDE; MICROFLUIDICS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84929224664     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7999     Document Type: Article

References (35)

1. Hochberg, F. H. et al. Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Rev. Mol. Diagn. 14, 439-452 (2014).
2. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
3. Agnihotri, S. et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J. Clin. Invest. 122, 253-266 (2012).
4. Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470-1476 (2008).
5. Simpson, R. J., Lim, J. W., Moritz, R. L. & Mathivanan, S. Exosomes: proteomic insights and diagnostic potential. Expert Rev. Proteomics 6, 267-283 (2009).
6. Taylor, D. D., Zacharias, W. & Gercel-Taylor, C. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol. Biol. 728, 235-246 (2011).
7. Thery, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569-579 (2002).
8. Lotvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 3, 26913 (2014).
9. Thery, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581-593 (2009).
10. Mathivanan, S., Ji, H. & Simpson, R. J. Exosomes: extracellular organelles important in intercellular communication. J. Proteomics 73, 1907-1920 (2010).
11. Graner, M. W. et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 23, 1541-1557 (2009).
12. Shao, H. et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat. Med. 18, 1835-1840 (2012).
13. Chen, W. W. et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol. Ther. Nucleic Acids 2, e109 (2013).
14. Im, H. et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat. Biotechnol. 32, 490-495 (2014).
15. Bredel, M. & Zentner, J. Brain-tumour drug resistance: the bare essentials. Lancet. Oncol. 3, 397-406 (2002).
16. Madhusudan, S. & Middleton, M. R. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev. 31, 603-617 (2005).
17. Weibel, D. B. et al. Torque-actuated valves for microfluidics. Anal. Chem. 77, 4726-4733 (2005).
18. Rho, J. et al. Magnetic nanosensor for detection and profiling of erythrocytederived microvesicles. ACS Nano 7, 11227-11233 (2013).
19. Mishima, K. et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 111, 483-488 (2006).
20. Wykosky, J., Gibo, D. M., Stanton, C. & Debinski, W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3, 541-551 (2005).
21. Townsend, D. M. & Tew, K. D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369-7375 (2003).
22. Chen, H. Y., Shao, C. J., Chen, F. R., Kwan, A. L. & Chen, Z. P. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int. J. Cancer 126, 1944-1954 (2010).
23. Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883 (2012).
24. Wrensch, M. et al. ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol. 7, 495-507 (2005).
25. Berger, W. et al. Overexpression of the human major vault protein in astrocytic brain tumor cells. Int. J. Cancer 94, 377-382 (2001).
26. Steiner, E., Holzmann, K., Elbling, L., Micksche, M. & Berger, W. Cellular functions of vaults and their involvement in multidrug resistance. Curr. Drug Targets 7, 923-934 (2006).
27. Kuan, C. T. et al. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 10, 468 (2010).
28. Qi, L. et al. Heterogeneity of primary glioblastoma cells in the expression of caspase-8 and the response to TRAIL-induced apoptosis. Apoptosis 16, 1150-1164 (2011).
29. Mehrian-Shai, R. et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc. Natl Acad. Sci. USA 104, 5563-5568 (2007).
30. Pols, M. S. & Klumperman, J. Trafficking and function of the tetraspanin CD63. Exp. Cell Res. 315, 1584-1592 (2009).
31. Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963-1972 (2010).
32. Muller, C. et al. Hematogenous dissemination of glioblastoma multiforme. Sci. Transl. Med. 6, 247ra101 (2014).
33. Sullivan, J. P. et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 4, 1299-1309 (2014).
34. Balaj, L. et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011).
35. Chung, J. et al. Microfluidic cell sorter (muFCS) for on-chip capture and analysis of single cells. Adv. Healthcare Mater. 1, 432-436 (2012).